Outcome of Guillain-Barré Syndrome (GBS) During Peripartum Period: A Hospital-Based Observational Study

Anil Kumar Patra, Marami Das, Saswati Sanyal Choudhury, Munindra Goswami, Vanlalzami K
Departments of Neurology and Obstetrics and Gynaecology, Gauhati Medical College and Hospital, Guwahati, Assam, India

Abstract

Objective: 1. To study the clinical profile, progression and outcome of GBS during peripartum period in a tertiary care hospital. 2. To identify the determinants of outcome in GBS during peripartum period. Background: Guillain-Barré Syndrome (GBS) is an acute, autoimmune disorder of the peripheral nervous system triggered by a bacterial or viral infection or other antecedent events. Modern day critical care has dramatically improved the outcome of GBS. GBS during pregnancy is rare with an annual incidence of 2.8/100,000 population. Pregnancy itself is a life-threatening condition and full of complications. GBS during pregnancy makes it more complicated in terms of both maternal and fetal care during peripartum period. Methods: This was a prospective study conducted by the Department of Neurology, Gauhati Medical College including 36 patients of GBS presenting during peripartum period in between December 2019 and November 2021. Their clinical and electrophysiological features were analyzed. Hughes grading, EGRIS, mEGOS, MRC sum score were used. The fetal outcome was observed and patients were followed up for GBS outcome at 3 months and 6 months. Results: The mean age of patients was 25.97 years. AIDP was the most common subtype found in 21 (58.33%) patients followed by AMAN in 7 (19.4%), AMSAN in 3 (8.33%). In 3 cases NCS was equivocal and in 3 cases intractable. Respiratory distress was found in 13 (36.1%) cases, out of which 4 (11.1%) required mechanical ventilation and 1 (2.8%) died. The pre-term birth rate and stillbirth rate were 35.7% (n = 10) and 8.33% (n = 3), respectively with 66.7% (n = 24) spontaneous vaginal delivery (SVD). At 3 month 26 (72.2%) had complete recovery, 5 (13.9%) and 4 (11.1%) had partial and poor recovery, respectively. 78.9% of primigravidae had complete recovery in comparison to 64.7% in multigravidae indicating better outcome in primigravidae in this study. Conclusion: The outcome of GBS during peripartum period is favorable. Primigravidae are more commonly affected but have better outcome than the multigravidae. The risk of developing GBS in pregnancy decreases significantly after delivery and is minimal after 2 weeks. GBS is not an indication for LSCS. Stillbirth rate and preterm birth rate is higher in pregnancy associated with GBS without fearsome neonatal complications.

Keywords: Multigravidae, peripartum Guillain Barré syndrome, primigravidae

Introduction

Guillain-Barré Syndrome (GBS) is an acute, autoimmune disorder of the peripheral nervous system triggered by bacterial or viral infection or other antecedent events. Annual incidence varies from 0.4-4 cases/100,000 population.[1] GBS during pregnancy is rare with annual incidence of 2.8/100,000 population.[2] A good leap of advancement has occurred in etiopathogenetic and clinical diversity but the management part has remained the same. Due to widespread availability of good supportive care and existing treatment modalities the outcome has improved.[3] Modern day critical care has dramatically improved the outcome of GBS as the mortality rate has reduced from 33% to 1-5% after introduction of positive pressure ventilation.[3] Natural history studies show that about 10 to 20% of patients remain severely disabled and about 5% die. Determinants of disease progression and recovery in GBS are still poorly understood. The timing of GBS onset during pregnancy varies. In an earlier study 13% of cases occurred in the first trimester, 47% in the second, and 40% in the third trimester.[4] In an Indian study one (12.5%) of the women presented in 2nd trimester, 3 (37.5%) of them in 3rd trimester, while 50% of them presented in the postnatal period.[5] There was an increased incidence in the postpartum period with an odds ratio of 2.93 (95% CI = 1.20-7.11).[6] 34.5% of women suffering from GBS during pregnancy required ventilatory support and the maternal mortality exceeded 10%.[7] In the study done by Chan et al.,[4] 23 women progressed beyond the second trimester and caesarean sections were performed in 14 (61%) cases. Uterine contraction is not affected despite of extensive peripheral nerve involvement in GBS and most of the patient normally deliver vaginally without any complications.[4] In a study done by Sharma et al.,[8] vaginal delivery was done in 42 cases, Caesarean section in 4 cases and instrumental delivery in 1 patient whereas premature rupture of membrane was seen in 3 patients and preterm delivery in 1 patient.[9] Among the neurological illnesses during pregnancy, GBS...
is a well-known but rare entity that makes its management more complicated in terms of both maternal and fetal care especially during peripartum period. This study will be helpful in assessing and managing GBS during peripartum period along with risk assessment and prognostication in terms of complications, maternal and fetal outcome.

**Methods**

This was a prospective study including 36 patients of GBS presenting during peripartum period in between December 2019 and November 2021. Approval was taken from the institutional ethical committee and written informed consent was taken from all patients/guardian of the patient. No additional intervention was tried because of the study and the normal treatment protocol of GBS was followed. A complete neurological examination (cranial nerve examination, muscle power charting, reflexes, and sensory examination, GBS disability scale and MRC sum score at admission were taken. Nerve conduction study (Motor, Sensory, and F response) were recorded. Brighton Criteria for Diagnosis of Guillian-Barré Syndrome (GBS) was used. Nerve conduction studies helped to confirm and categorize the diagnosis and subtypes of GBS. Based on NCS, patients were categorized into AIDP (Acute inflammatory demyelinating polyradiculoneuropathy), AMAN (Acute motor axonal neuropathy), AMSAN (Acute motor-sensory axonal neuropathy), In-excitable (absent CMAP in all motor nerves), Equivocal group.

A record of follow up at 4 weeks, 12 weeks, and 6 months was obtained for all patients which was a scale based assessment of disability (using Hughes GBS disability scale) based on follow up. The primary outcome measure was the disability at 3 months and 6 months analysis. The outcome in those who were able to perform their daily activity independently were taken as complete recovery whereas those who were able to do daily activity with help was taken as partial and bedridden or wheelchair bound were taken as poor recovery. The complete recovery cases were taken as good outcome and the rest were taken as bad outcome and analysed. Age, Age >30 years, Day of hospitalization after onset of illness and peak of illness was reached at a mean duration of 8.33 ± 4.45 days after onset of illness and peak of illness was reached at a mean duration of 12.17 ± 4.6 days. Majority of patients were primigravida (n = 19) followed by 11 in gravida 2, 5 in gravida 3 and 1 in gravida 4. The trend was similar in para with 21 in para 1, 12 in para 2 and 3 in para 3. Maximum number (n = 14) of patients were at 37 weeks of gestation when disease onset occurred. Out of which 19 were preterm and 17 at term stage of pregnancy. Out of 36 peripartum patients, 28 were antepartum and 8 were postpartum. 6 out of 8 postpartum cases developed weakness on same day of delivery. 20 (55.6%) cases had antecedent illness with fever in 9 (25%), diarrhoea and sore throat in 5 (13.9%) each. AIDP was the most common subtype found in 21 (58.3%) patients followed by AMAN in 7 (19.4%), AMSAN in 3 (8.3%). In 3 cases, NCS was equivocal and 3 cases were inexcitable. Fever and diarrhoea were the most common antecedent illness in AIDP and AMAN respectively. The detailed clinical profile is mentioned in Table 1. The mean EGRIS and mEGOS were 25.97 years (median 25, range 19-36 years). The patients were analyzed for the predictors of outcome.

A record of follow up at 4 weeks, 12 weeks, and 6 months was obtained for all patients which was a scale based assessment of disability (using Hughes GBS disability scale) based on follow up. The primary outcome measure was the disability at 3 months and 6 months analysis. The outcome in those who were able to perform their daily activity independently were taken as complete recovery whereas those who were able to do daily activity with help was taken as partial and bedridden or wheelchair bound were taken as poor recovery. The complete recovery cases were taken as good outcome and the rest were taken as bad outcome and analysed. Age, Age >30 years, Day of hospitalization after onset of illness and peak of illness was reached at a mean duration of 8.33 ± 4.45 days after onset of illness and peak of illness was reached at a mean duration of 12.17 ± 4.6 days. Majority of patients were primigravida (n = 19) followed by 11 in gravida 2, 5 in gravida 3 and 1 in gravida 4. The trend was similar in para with 21 in para 1, 12 in para 2 and 3 in para 3. Maximum number (n = 14) of patients were at 37 weeks of gestation when disease onset occurred. Out of which 19 were preterm and 17 at term stage of pregnancy. Out of 36 peripartum patients, 28 were antepartum and 8 were postpartum. 6 out of 8 postpartum cases developed weakness on same day of delivery. 20 (55.6%) cases had antecedent illness with fever in 9 (25%), diarrhoea and sore throat in 5 (13.9%) each. AIDP was the most common subtype found in 21 (58.3%) patients followed by AMAN in 7 (19.4%), AMSAN in 3 (8.3%). In 3 cases, NCS was equivocal and 3 cases were inexcitable. Fever and diarrhoea were the most common antecedent illness in AIDP and AMAN respectively. The detailed clinical profile is mentioned in Table 1. The mean EGRIS and mEGOS were 25.97 years (median 25, range 19-36 years). The patients were analyzed for the predictors of outcome.

**Results**

A total of 36 patients were included with a mean age of 25.97 years (median 25, range 19-36 years). The patients presented with a mean duration of 8.33 ± 4.45 days after onset of illness and peak of illness was reached at a mean duration of 12.17 ± 4.6 days. Majority of patients were primigravida (n = 19) followed by 11 in gravida 2, 5 in gravida 3 and 1 in gravida 4. The trend was similar in para with 21 in para 1, 12 in para 2 and 3 in para 3. Maximum number (n = 14) of patients were at 37 weeks of gestation when disease onset occurred. Out of which 19 were preterm and 17 at term stage of pregnancy. Out of 36 peripartum patients, 28 were antepartum and 8 were postpartum. 6 out of 8 postpartum cases developed weakness on same day of delivery. 20 (55.6%) cases had antecedent illness with fever in 9 (25%), diarrhoea and sore throat in 5 (13.9%) each. AIDP was the most common subtype found in 21 (58.3%) patients followed by AMAN in 7 (19.4%), AMSAN in 3 (8.3%). In 3 cases, NCS was equivocal and 3 cases were inexcitable. Fever and diarrhoea were the most common antecedent illness in AIDP and AMAN respectively. The detailed clinical profile is mentioned in Table 1. The mean EGRIS and mEGOS were 25.97 years (median 25, range 19-36 years). The patients were analyzed for the predictors of outcome.

**Pregnancy outcome**

Out of 36 patients spontaneous vaginal delivery was the most common mode of delivery in 24 (66.67%) followed by caesarean section in 10 (27.78%) patients. In two cases,
10 (33.3%) out of 30 GBS during pregnancy

This delay in

141.1±124.73

0.025

3.2±1.14

3

[5]

3

0.54

study and Zhang

4

35.77±11.67

26.19±4.34

1.31±0.62

30.44±14.05

25.97±4.97 (median 25 years). Shrivastava M et al. [9] found the mean age 40.69 ± 18.8 years. This may be because pregnancy usually occurs more during the early reproductive age in India. Majority of patients were primigravidae (n = 19). Maximum number (n = 10) of patients presented at 37 weeks of gestation and most of the patients presented antepartum (n = 28). Sharma et al. [9] found 13 (27%) out of 47 cases in primigravida. [8] In a study done by Rupalakshmi et al., [3] out of 8 cases 3 (37.5%) were primigravida. [3] Only 8 (22.2%) of patients were postpartum out of which 6 had disease onset on the same day of delivery, one each on the 3rd and 14th day of postpartum. This indicates that the risk of developing GBS in pregnancy decreases significantly after delivery and minimal after 2 weeks. The mean duration of presentation from onset of disease in days was 6.69 ± 2.93 similar to 5.7 days in the study by Sharma et al. [9] but earlier than the study by Kalita et al. (10.6 days). [8,10] This delay in presentation might be due to initial nonspecific symptoms that mimic physiological changes in pregnancy. [4]

20 (55.5%) had facial nerve palsy which is more in comparison to the study by Sharma et al. [9] in pregnant GBS where it was found in 10% cases only. Zhang et al. [8] found sensory involvement in 52.7% of cases. Cranial nerve involvement was similar to Kalita et al. [10] study and Zhang et al. [11] study (50.5%), whereas in two other studies done in pregnant GBS by Sharma et al. [9] and Shrivastava et al. [9] a very high number of cases that is 35 (75.2%) and 39 (87.9%) respectively were not having any cranial nerve involvement. In a study by Chan et al., [11] 10 (33.3%) out of 30 GBS during pregnancy

Table 2: Outcome of peripartum GBS cases

| Variables                  | Case       |
|----------------------------|------------|
| mEGOS                     | 4.64±1.95  |
| EGRIS                     | 3.67±1.43  |
| MRC sum score day 1        | 30.44±14.05|
| Hughes grade day 1         | 3.89±0.57  |
| Hughes grade 4 week        | 3.31±0.85  |
| Hughes grade 12 week       | 2.03±1.34  |

3-month recovery

Complete: 26 (72.2%)
Partial: 5 (13.9%)
Poor: 4 (11.1%)
Death: 1 (2.8%)

6-month recovery

Complete: 26 (72.2%)
Partial: 6 (16.7%)
Poor: 3 (8.3%)
Death: 1 (2.8%)

Table 3: Predictors of outcome in peripartum GBS

| Variables                  | Good Outcome (n=26) | Bad Outcome (n=10) | P       |
|----------------------------|---------------------|--------------------|---------|
| Age                        | 26.19±4.34          | 25.40±6.55         | 0.675   |
| Day of presentation        | 7.85±4.13           | 9.6±5.25           | 0.297   |
| Day of peak illness        | 11.08±3.46          | 15±6.07            | 0.02    |
| Hughes day 1               | 3.73±0.53           | 4.3±0.48           | 0.006   |
| Hughes 4 week              | 2.96±0.66           | 4.2±0.63           | <0.001  |
| Hughes 12 week             | 1.31±0.62           | 3.8±0.92           | <0.001  |
| mEGOS                      | 4.12±2.03           | 6±0.82             | 0.008   |
| EGRIS                      | 3.31±1.46           | 4.6±0.84           | 0.013   |
| MRC D1                     | 35.77±11.67         | 16.6±9.76          | <0.001  |
| CSF cells                  | 3±0.75              | 3.2±1.14           | 0.54    |
| CSF protein                | 98.23±69.01         | 141±124.73         | 0.196   |
| Age >30 years              | 3                   | 3                   | 0.183   |
| Autonomic dysfunction      | 4                   | 4                   | 0.112   |
| Respiratory distress       | 6                   | 7                   | 0.009   |
| Albuminocytological dissociation | 16               | 6                   | 0.932   |
| F wave abnormality         | 14                  | 3                   | 0.63    |
| Non-stimulable nerves      | 7                   | 8                   | 0.004   |
| IVlg                       | 23                  | 10                  | 0.2619  |
| Mechanical ventilation     | 1                   | 3                   | 0.025   |

Neurological outcome

1 (2.8%) patient died of sepsis. At 3 months, 26 (72.2%) had complete recovery whereas 5 (13.9%) and 4 (11.1%) had partial and poor recovery, respectively. At 6 months, 1 out of the poor recovery patient improved to partial recovery stage and the complete recovery patients remained the same that is 72.2%. The detailed neurological outcome mentioned in Table 2. At 3 months, 78.9% of primigravida had complete recovery but 64.7% of multigravida achieved the same.

Predictors of outcome

While the age, day of presentation after onset, the day of peak illness were statistically insignificant for outcome, the high Hughes grading at day 1, 4 weeks, 12 weeks, EGRIS, mEGOS, low MRC sum score day 1, presence of respiratory distress, non-stimulable nerves in NCS, and requirement of mechanical ventilation were statistically significant for bad outcome measure at 3 months recovery. The detailed predictors of outcome mentioned in Table 3.

DISCUSSION

The patients were relatively younger with mean age of 25.97 ± 4.97 (median 25 years). Shrivastava M et al. [9] found the mean age 40.69 ± 18.8 years. This may be because pregnancy usually occurs more during the early reproductive age in India. Majority of patients were primigravidae (n = 19). Maximum number (n = 10) of patients presented at 37 weeks of gestation and most of the patients presented antepartum (n = 28). Sharma et al. [9] found 13 (27%) out of 47 cases in primigravida. [8] In a study done by Rupalakshmi et al., [3] out of 8 cases 3 (37.5%) were primigravida. [3] Only 8 (22.2%) of patients were postpartum out of which 6 had disease onset on the same day of delivery, one each on the 3rd and 14th day of postpartum. This indicates that the risk of developing GBS in pregnancy decreases significantly after delivery and minimal after 2 weeks. The mean duration of presentation from onset of disease in days was 6.69 ± 2.93 similar to 5.7 days in the study by Sharma et al. [9] but earlier than the study by Kalita et al. (10.6 days). [8,10] This delay in presentation might be due to initial nonspecific symptoms that mimic physiological changes in pregnancy. [4]

20 (55.5%) had facial nerve palsy which is more in comparison to the study by Sharma et al. [9] in pregnant GBS where it was found in 10% cases only. Zhang et al. [8] found sensory involvement in 52.7% of cases. Cranial nerve involvement was similar to Kalita et al. [10] study and Zhang et al. [11] study (50.5%), whereas in two other studies done in pregnant GBS by Sharma et al. [9] and Shrivastava et al. [9] a very high number of cases that is 35 (75.2%) and 39 (87.9%) respectively were not having any cranial nerve involvement. In a study by Chan et al., [11] 10 (33.3%) out of 30 GBS during pregnancy
required mechanical ventilation whereas only 4.2% required in our study.

AIDP (58.3%) cases were less in comparison to 60.36% in Zhang et al. study, 73.8% in Kalita et al.[10] study and 72.7% in Shrivastava et al.[9] study whereas more than that of Sharma et al.[8] study (50%). In two other study by Sharma et al.,[5] (43.9%) and Shrivastava et al.[9] (27.7%) in pregnant GBS more percentage of patients were AMAN. AMSAN subtype was more in this study i.e., 11.1% in comparison to 3% by Sharma et al. and 4.6% by Kalita et al.[8,10] More percentage of AMAN and AMSAN were found and less percentage of AIDP in comparison to pre-existing studies. Only 2% patients in the study by Sharma et al.,[8] 33.7% in Kalita et al.[10] 36.04% in the study by Zhang et al.[11] and 37.5% in the study by Rupalakshmi et al.[7] received IVIg whereas 91.7% in this study received IVIg. The very high percentage of patient in our study received IVIg because it was easily available and free of cost. It was given to all the patients who fulfill the indication of IVIg therapy. In this study only 1 (2.8%) patient died. In Rajabally et al.[12] analysis, 61 (4.4%) out of 1391 patient died. mortality was similar to many of the studies except 25% of pregnant GBS in a study of 8 patient by Rupalakshmi et al.[7]

At 6 month 88.9% of cases were able to walk unaided in this study similar to 100 (82%) out of 122 in analysis done by Rajabally et al.[12] 72.2% of our patient had complete recovery at 3 months in comparison to 46.6% of the study by Kalita et al.[10] 78.9% of primigravidae have complete recovery in comparison to 64.7% in multigravidae indicating better outcome in primigravidae in this study. Need for mechanical ventilation, Preceding diarrhoea, Low MRC Sum Score at admission, Short interval between weakness onset and admission, Facial and/or bulbar weakness, electrophysiologically Inexcitable nerves were indicators of poor outcome in pooled analysis done by Rajabally et al.[12] Kalita et al.[10] found similar outcome predictors like cranial nerve involvement, bulbar weakness, higher disability grade, dysautonomia, generalized hyporeflexia, inexcitable nerves, mechanical ventilation as statistically significant whereas day of admission, use of IVIg were nonsignificant. Similar to this study, the duration of admission after onset and use of IVIg was not significant but low MRC sum score, requirement of mechanical ventilation statistically significant as prognostic indicator by Zhang et al.[11] Wen et al.[13] also found IVIg treatment non-significant as an indicator of good outcome. The comparison of different studies mentioned in Table 4.

24 (66.67%) out of 36 patients had spontaneous vaginal delivery followed by caesarean section in 10 (27.78%) patients similar to that of Rupalakshmi et al.[7] where 25% had LSCS and 75% had vaginal delivery. Sharma et al.[8] who studied 47 pregnant GBS found 89.3% cases to have spontaneous vaginal delivery and 2.1% requiring ventouse. Chan et al.[4] in his 23 GBS patients found that 61% required LSCS, 34.7% having SVD and only one requiring instrumental delivery by forceps. In study done by Sharma N et al.[4] out of 4636 deliveries, 31.1% underwent LSCS and 68.9% had vaginal delivery. Maskey S et al.[15] found that out of 862 deliveries 36.8% were LSCS whereas 63.1% and 0.51% were vaginal deliveries and instrumental deliveries, respectively. The rate of LSCS in our institution where study was done is 50.6% which is higher than the LSCS rate in peripartum GBS in our study indicating that GBS is not an indication for LSCS.

Out of 36 deliveries, in 3 (8.33%) fetal outcome were stillbirth in this study. In the study done by Chan et al.,[4] preterm deliveries occurred in eight (34.7%) cases, of which three had spontaneous labour while five were iatrogenic preterm deliveries due to deterioration of maternal neurological condition (three cases) or pre-eclampsia (two cases). In our study, 11 (30.6%) out of 36 deliveries were preterm out of which 2 were LSCS and 9 were SVD. Out of 11 preterm birth one was postpartum GBS and 10 were antepartum. 10 out of 11 of our preterm birth mothers had GBS antepartum. Out of 36 peripartum patient, 28 were antepartum and 8 were postpartum. If we consider the antepartum GBS, the preterm birth rate will be much higher that is 10 (35.7%) out of 28. In the study by Chan et al.,[4] only in 1 (4.3%) out of 23 deliveries there was fetal death due to maternal death and rest 22 cases were

| Parameters                  | In this study (%) | Sharma et al.[8] (n=47) (%) | Kalita et al.[10] (n=328) (%) | Shrivastava et al.[9] (n=47) (%) |
|-----------------------------|-------------------|-------------------------------|-------------------------------|----------------------------------|
| Facial weakness             | 20 (55.5%)        | 5 (10%)                       | 145 (44.2%)                   |                                  |
| Bulbar weakness             | 14 (38.8%)        | 7 (14.8%)                     | 99 (30.2%)                    |                                  |
| Sensory symptoms            | 16 (44.4%)        | 32 (68%)                      | 173 (52.7%)                   |                                  |
| Autonomic dysfunction       | 8 (22.2%)         | 9 (19.1%)                     | 67 (20.7%)                    |                                  |
| Respiratory involvement     | 13 (36.1%)        | 2 (4.2%)                      | 100 (30.5%)                   |                                  |
| Ventilatory support         | 4 (11.4%)         | 2 (4.2%)                      | 43 (13.1%)                    |                                  |
| AIDP                        | 21 (58.3%)        | 33 (50%)                      | 272 (73.8%)                   |                                  |
| AMAN                        | 7 (19.4%)         | 29 (43.9%)                    | 44 (13.4%)                    |                                  |
| AMSAN                       | 3 (8.3%)          | 2 (3%)                        | 15 (4.6%)                     |                                  |
| INESCITABLE                 | 3 (8.3%)          |                              | 8 (2.4%)                      |                                  |
| EQUIVOCAL                   | 2 (5.6%)          | 2 (3%)                        | 19 (5.8%)                     |                                  |

Table 4: Comparison of different studies

---

Patra, et al.: Observational study on outcome of GBS during peripartum period

Annals of Indian Academy of Neurology ¦ Volume 25 ¦ Issue 3 ¦ May-June 2022
normal. The fetal death in our study was more. In the study done by Rupalakshmi et al.,[15] 3 (37.5%) out of 8 deliveries were pre-term and 2 (25%) was stillbirth. The percentage of preterm delivery and stillbirth in our study is similar to that of Chan et al.[4] and Sharma et al. but less than the study by Rupalakshmi et al. where sample size (n = 8) was small. The stillbirth rate and preterm birth rate in our institution where study was conducted is 4.79% and 20.6% respectively. The preterm birth rate (35.7%) in our study is much higher than global data (11%).[16] GBS during pregnancy can be a risk factor for preterm birth and stillbirth and can affect the fetal outcome adversely. In the study by Chan et al.,[4] out of 22 reported live births, only one baby was having neonatal GBS and 20 babies were normal without any complications. In our study, out of 33 reported live birth one baby required neonatal ICU care and recovered completely. No neonatal GBS was reported. In the study by Sharma et al.,[15] five babies required NICU care. Though preterm birth and stillbirth rate are higher, most of the babies born out of GBS mother were normal without any complication.

The physiological changes and decrease ambulation during later part of pregnancy may mask the initial sign and symptoms of GBS hence physician must be vigilant for early diagnosis and definitive management for a better fetal and maternal outcome. GBS is not an indication for LSCS. Stillbirth rate and preterm birth rate is higher in pregnancy associated with GBS without fearsome neonatal complications. The reason may be because most of the preterm birth were at late preterm that is not less than 34 weeks (not modest to extreme) which is a scope for further study in larger group of GBS patients during pregnancy.

**Conclusion**

The outcome of GBS during peripartum period is favorable. Primigravidae are more commonly affected but have better outcome than the multigravidae. The risk of developing GBS in pregnancy decreases significantly after delivery and is minimal after 2 weeks. GBS is not an indication for LSCS. Stillbirth rate and preterm birth rate is higher in pregnancy associated with GBS without fearsome neonatal complications.

**Declaration of patient consent**

The authors certify that they have obtained all appropriate patient consent forms. In the form, the patient(s) has/have given his/her/their consent for his/her/their images and other clinical information to be reported in the journal. The patients understand that their names and initials will not be published and due efforts will be made to conceal their identity, but anonymity cannot be guaranteed.

**Financial support and sponsorship**

Nil.

**Conflicts of interest**

There are no conflicts of interest.

**References**

1. Hughes RA, Rees JH. Clinical and epidemiologic features of Guillain-Barre syndrome. J Infect Dis 1997;176(Suppl 2):S92-8.
2. Myers TR, McCarthy NL, Panagiotakopoulos L, Omer SB. Estimation of the incidence of Guillain-Barre syndrome during pregnancy in United States. Open Forum Infect Dis 2019;6:ofz071. doi: 10.1093/ofid/ofz071.
3. Alshekhlee A, Hussein Z, Sultan B, Katriji B. Guillain Barre syndrome: Incidence and mortality rates in US hospitals. Neurology 2008;70:1608-13.
4. Chan LY-S, Tsui M H-Y, Leung TN. Guillain-Barre syndrome in pregnancy. Acta Obstet Gynecol Scand 2004;83:319-25.
5. Rupalakshmi V, Shetty SK. Guillain–Barre syndrome in pregnancy and its association with maternal and perinatal outcome. Muller J Med Sci Res 2019;10:58-61.
6. Cheng Q, Jiang GX, Fredriksson S, Link H, de Pedro-Cuesta J. Increased incidence of Guillain-Barré syndrome postpartum. Epidemiology 1998;9:601-43.
7. Nelson LH, McLean WT Jr. Management of Landry-Guilain- Barré syndrome in pregnancy. Obstet Gynecol 1985;65(Suppl 3):25S-95.
8. Sharma SR, Sharma N, Masaraf HM, Singh SA. Guillain-Barre syndrome complicating pregnancy and correlation with maternal and fetal outcome in North Eastern India: A retrospective study. Ann Indian Acad Neurol 2015;18:215-8.
9. Shirivastava M, Shah N, Navaid S. Guillain-Barre syndrome: Demographic, clinical profile and seasonal variation in tertiary care centre of central India. Indian J Med Res 2017;145:203-8.
10. Kalita J, Misra UK, Goyal G, Das M. Guillain-Barré Syndrome: Subtypes and predictors of outcome From India. J Peripher Nerv Syst 2014;19:36-43.
11. Zhang Y, Zhao Y, Wang Y. Prognostic factor of Guillain Barre syndrome: A 111 case retrospective review. Chin Neurosurg J 2018;4:14.
12. Rajabally YA, Uncini A. Outcome and its predictors in Guillaine-Barré syndrome. J Neurol Neurosurg Psychiatry 2012;83:711-8.
13. Wen P, Wang L, Liu H, Gong L, Ji H, Wu H, et al. Risk factor for the severity of gullian-barre syndrome and predictors of short-term prognosis of severe Guillain-Barre syndrome. Sci Rep 202;11:11578.
14. Sharma N, Jhanwar A, Klebanoff MA, Rayburn WF. Isolated oligohydramnios is not associated with adverse perinatal outcomes. BJOG 2018;7:2672-6.
15. Maskey S, Bajracharya M, Bhandari S. Prevalence of caesarean section and its indications in a tertiary care hospital. JNMA J Nepal Med Assoc 2019;57:70-3.
16. March of Dimes, PMNCH, Save the children, WHO. Born Too Soon: The Global action report on preterm Birth. Eds CP Howson, MV Kinney, JE Lawn. World Health Organization. Geneva, 2012.